Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Spezial Report: NASDAQ-FinTech mit 3.000% Wachstum und 500% Kurs-Chance!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ACMZ | ISIN: US4622221004 | Ticker-Symbol: ISI
Tradegate
17.05.24
21:31 Uhr
33,950 Euro
-0,380
-1,11 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
IONIS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
IONIS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
33,91034,75013:04
34,17034,48017.05.

Aktuelle News zur IONIS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrIonis (IONS), Biogen Down on Ending Development of ALS Drug11
DoIonis and Biogen discontinue experimental ALS drug after Phase I/II flop2
DoBiogen also drops collaboration with Ionis on Angelman syndrome candidate4
DoBiogen, Ionis shelve ALS drug following study failure5
DoTale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another2
DoBiogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data5
DoBiogen, Ionis to discontinue development of ALS drug8
DoBiogen Inc.: Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis304Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis continue...
► Artikel lesen
DoIonis Pharmaceuticals, Inc.: Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis223Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue...
► Artikel lesen
09.05.Vue Health scopes out Ionis alum as new digital innovation chief3
08.05.Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript4
08.05.The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals6
08.05.Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss6
07.05.IONIS PHARMACEUTICALS INC - 10-Q, Quarterly Report3
07.05.IONIS PHARMACEUTICALS INC - 8-K, Current Report2
07.05.Ionis Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary7
07.05.IONIS PHARMACEUTICALS INC Q1 Loss increases, but beats estimates3
07.05.Ionis Pharmaceuticals GAAP EPS of -$0.98 beats by $0.09, revenue of $119M misses by $17.41M5
07.05.Ionis Pharmaceuticals, Inc.: Ionis reports first quarter 2024 financial results180WAINUATM launch on track; EU and Canada approval decisions expected this year Olezarsen NDA submitted to FDA for FCS; preparing EU regulatory submission Positive Phase 3 donidalorsen data for HAE;...
► Artikel lesen
10.04.Wolfe upgrades Ionis to outperform, cites upcoming catalysts13
Seite:  Weiter >>
98 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1